Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  FUJIFILM Holdings Corporation    4901   JP3814000000

FUJIFILM HOLDINGS CORPORATION

(4901)
  Report
SummaryChartsNewsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan

10/21/2020 | 11:50pm EST

TOKYO, Oct 22 (Reuters) - Japan's Fujifilm Holdings Corp said on Thursday it has partnered with Shanghai-based Carelink Pharmaceutical Co to seek approval in China for Avigan to treat COVID-19 and influenza.

Carelink will use Fujifilm's data on Avigan's treatment of novel coronavirus infections and influenza to seek imported drug approval in China, Fujifilm said in a statement. The two companies also plan to develop an injectable form of the drug.

Fujifilm said last week it was seeking approval for Avigan as a treatment for COVID-19 in Japan. That followed results from a late-stage study in Japan that showed the antiviral drug reduced recovery time for patients with non-severe symptoms.

Avigan, originally developed as an emergency flu drug and known generically worldwide as favipiravir, has been approved in India and Russia to treat COVID-19.

Fujifilm sold global rights in July on Avigan to India's Dr Reddy's Laboratories and Dubai-based Global Response Aid. That deal excluded China, Japan and Russia.

Last month, Fujifilm said the late-stage study of 156 COVID-19 patients in Japan showed that symptoms of those treated with Avigan improved after 11.9 days, versus 14.7 days for a placebo group.

Results of the study, conducted by subsidiary Fujifilm Toyama Chemical, were found to be statistically significant. (Reporting by Rocky Swift; Editing by Christian Schmollinger and Muralikumar Anantharaman)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
DR. REDDY'S LABORATORIES LIMITED 1.92% 4898.8 End-of-day quote.70.27%
FUJIFILM HOLDINGS CORPORATION 0.10% 5756 End-of-day quote.10.06%
US DOLLAR / RUSSIAN ROUBLE (USD/RUB) 0.16% 75.975 Delayed Quote.22.05%
All news about FUJIFILM HOLDINGS CORPORATION
11/13FUJIFILM : Cellular Dynamics and Lonza Agree to Expand the Availability and Use ..
AQ
11/05WHO-led COVID drug scheme doubles down on antibodies, steroids and shuns remd..
RE
11/05FUJIFILM HOLDINGS CORPORATION : half-yearly earnings release
10/30In Japan's Nagasaki, some glimmers of economic revival
RE
10/22FUJIFILM : Fuji Xerox in court over alleged unfair contract terms
AQ
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/21Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/16Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
More news
Financials
Sales 2021 2 200 B 21 125 M 21 125 M
Net income 2021 127 B 1 220 M 1 220 M
Net Debt 2021 170 B 1 629 M 1 629 M
P/E ratio 2021 17,9x
Yield 2021 1,68%
Capitalization 2 291 B 22 022 M 21 999 M
EV / Sales 2021 1,12x
EV / Sales 2022 1,05x
Nbr of Employees 73 906
Free-Float 73,8%
Chart FUJIFILM HOLDINGS CORPORATION
Duration : Period :
FUJIFILM Holdings Corporation Technical Analysis Chart | 4901 | JP3814000000 | MarketScreener
Technical analysis trends FUJIFILM HOLDINGS CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Average target price 6 164,67 JPY
Last Close Price 5 730,00 JPY
Spread / Highest target 20,4%
Spread / Average Target 7,59%
Spread / Lowest Target -12,4%
EPS Revisions
Managers
NameTitle
Shigetaka Komori Chairman & Group Chief Executive Officer
Kenji Sukeno President, Group COO & Representative Director
Takashi Iwasaki Director & Chief Technology Officer
Kouichi Tamai Director & Vice President
Takatoshi Ishikawa Director
Sector and Competitors
1st jan.Capitalization (M$)
FUJIFILM HOLDINGS CORPORATION10.06%22 022
TECAN GROUP LTD.42.87%5 132
CANON MARKETING JAPAN INC.-11.85%2 824
PAR TECHNOLOGY CORPORATION82.27%1 195
SATO HOLDINGS CORPORATION-38.25%693